These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 20434707)
21. [Strategies of breast cancer treatment based on determination of biological subtype]. Semiglazov VF Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922 [No Abstract] [Full Text] [Related]
23. [Antitumour effects of bisphosphonates in breast cancer]. van de Ven S; Kroep JR; Hamdy NA; Sleeboom HP; Nortier HW Ned Tijdschr Geneeskd; 2010; 154():A1951. PubMed ID: 21083955 [TBL] [Abstract][Full Text] [Related]
24. Breast cancer: CTCs - a predictive approach for targeted cancer therapy. Errico A Nat Rev Clin Oncol; 2014 Sep; 11(9):501. PubMed ID: 25073006 [No Abstract] [Full Text] [Related]
25. Therapy: using CTCs to test drug sensitivity. Alderton GK Nat Rev Cancer; 2014 Sep; 14(9):576. PubMed ID: 25079656 [No Abstract] [Full Text] [Related]
26. Anticancer drugs: using CTCs to test drug sensitivity. Alderton GK Nat Rev Drug Discov; 2014 Sep; 13(9):654. PubMed ID: 25176433 [No Abstract] [Full Text] [Related]
27. Adjuvant therapy of breast cancer - bisphosphonates. Saarto T Cancer Treat Res; 2009; 151():163-77. PubMed ID: 19593512 [No Abstract] [Full Text] [Related]
28. Recent developments in bisphosphonates for patients with metastatic breast cancer. Gainford MC; Dranitsaris G; Clemons M BMJ; 2005 Apr; 330(7494):769-73. PubMed ID: 15802719 [No Abstract] [Full Text] [Related]
29. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Mouridsen HT; Lønning P; Beckmann MW; Blackwell K; Doughty J; Gligorov J; Llombart-Cussac A; Robidoux A; Thürlimann B; Gnant M Expert Rev Anticancer Ther; 2010 Nov; 10(11):1825-36. PubMed ID: 20883112 [TBL] [Abstract][Full Text] [Related]
30. [Is pamidronate or clodronate better?]. Adam Z Vnitr Lek; 2002 Apr; 48(4):357. PubMed ID: 12075601 [No Abstract] [Full Text] [Related]
33. Effects of bone-targeted agents on cancer progression and mortality. Coleman R; Gnant M; Morgan G; Clezardin P J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060 [TBL] [Abstract][Full Text] [Related]
34. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Barok M; Balázs M; Nagy P; Rákosy Z; Treszl A; Tóth E; Juhász I; Park JW; Isola J; Vereb G; Szöllosi J Cancer Lett; 2008 Feb; 260(1-2):198-208. PubMed ID: 18096313 [TBL] [Abstract][Full Text] [Related]
35. Chemotherapy. A useful tool against cancer. Mayo Clin Womens Healthsource; 2007 Apr; 11(4):4-5. PubMed ID: 17351553 [No Abstract] [Full Text] [Related]
36. Measuring circulating tumor cells as a surrogate end point for adjuvant therapy of breast cancer: what do they mean and what should we do about them? Bear HD J Clin Oncol; 2008 Mar; 26(8):1195-7. PubMed ID: 18323543 [No Abstract] [Full Text] [Related]
37. [Medical treatment of bone metastases]. Tubiana-Hulin M Bull Cancer Radiother; 1996; 83(4):299-304. PubMed ID: 9081331 [No Abstract] [Full Text] [Related]
38. Bisphosphonates in breast cancer: antitumor effects. Aft R Clin Adv Hematol Oncol; 2011 Apr; 9(4):292-9. PubMed ID: 21558988 [TBL] [Abstract][Full Text] [Related]
39. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Rack B; Jückstock J; Günthner-Biller M; Andergassen U; Neugebauer J; Hepp P; Schoberth A; Mayr D; Zwingers T; Schindlbeck C; Friese K; Janni W Arch Gynecol Obstet; 2012 Feb; 285(2):485-92. PubMed ID: 21717141 [TBL] [Abstract][Full Text] [Related]
40. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]